Fly over the United States and China to the top of the world's largest market in 2020

Source: pharmaceutical economic news 2011-05-09 the strong growth momentum of China's pharmaceutical market in the past year shocked the world According to the 2010 medical market statistics released by IMS recently, China ranks first in the growth rate of the world's pharmaceutical market with a growth rate of 21.9%, far higher than the overall growth rate of 4.2% of the world's pharmaceutical market According to IMS forecast, China's pharmaceutical market will still maintain a compound growth rate of 20.1% from 2010 to 2015, and China will surpass Japan to become the second largest pharmaceutical market in the world in 2016 On April 19, at the manager seminar entitled "going abroad - a successful strategy to enter the US market" held in Guangzhou, the research data released by chinabio, a US research institution, even pointed out that China might surpass the US in 2020 and become the largest pharmaceutical market in the world This is not groundless As Gao Ruige, President and co-founder of angel investment group and President and founder of China Bio RLLC, said at the meeting, "China's pharmaceutical industry has made a huge leap in 2010." No matter from the perspective of capital or technological innovation, China's pharmaceutical industry has great potential In 2010, with the launch of the new medical reform, China's medical and health market was favored by investors, and more and more capital began to pay attention to the investment opportunities in the field of China's medical and health industry According to the statistics released by chinabio at the meeting, there were 58 cases of venture capital in China's medical and health industry in 2010, 32% more than 44 cases in 2009; the amount of venture capital also broke the $1 billion mark for the first time, reaching a record high of $1.013 billion From the perspective of industry segmentation, the pharmaceutical industry occupies the main position, accounting for 63% of the total venture capital, while the medical service industry and medical devices are relatively small "The pharmaceutical industry has become the focus of venture capital." Xu Ming, director of the comprehensive Department of the China Medical Insurance chamber of Commerce, said that "the expansion of the new medical reform and the policy inclination of the 12th Five Year Plan have brought development opportunities for the pharmaceutical industry Investors are seeing high growth in the industry " In the past 2010, the pharmaceutical industry also staged a vigorous "listing boom" According to the statistics of chinabio, in 2010, the number of IPOs completed by the pharmaceutical industry was 33, double the 15 in 2009; the financing was nearly 6 billion US dollars, 48% higher than the 3995 million US dollars in 2009 In terms of IPO quantity and financing amount, the pharmaceutical industry accounts for 79% of the total, followed by the medical device industry and the medical service industry In addition, the pace of M & A integration in the pharmaceutical industry is also greatly accelerated According to the statistics of chinabio, in 2010, the number of M & A cases in China's medical and health industry was 64, nearly double the 23 cases in 2009 The value of M & A transactions exceeded US $3.4 billion, an increase of more than seven times compared with us $44 million in 2009 At the same time, the average transaction amount reached US $70 million There is no doubt that the pharmaceutical industry is still the main force of M & A, accounting for 81% of the total amount of M & A The above data shows that the capital of the pharmaceutical industry is very active in terms of both the number of investment cases and the amount of investment In particular, the biomedical industry ranked among the top three most popular investment industries in 2010 "On the one hand, since the financial crisis, the country has accumulated a large amount of funds from 4 trillion investment to stimulate economic growth to the massive credit in 2009 and 2010; on the other hand, the regulation and control of the coal mining industry and the real estate industry are likely to guide some of the funds or the funds originally intended to be invested in these fields to transfer to the pharmaceutical industry This is also one of the main reasons why PE and M & A in the pharmaceutical industry have sprung up in the past two years " Some people in the equity investment industry pointed out In the first quarter of the year, people in the equity investment industry also pointed out that whether the increase of PE / VC investment or the number of IPOs indicates that the market has a high degree of recognition for the pharmaceutical industry "The pharmaceutical industry itself is a sunrise industry with good growth and investment value." "A large number of funds into the pharmaceutical industry has a significant role in promoting the development of the industry A large number of small and medium-sized enterprises can obtain much-needed funds, increase R & D investment, purchase new equipment and personnel training can be strengthened, and accelerate the R & D process of new products, which will bring explosive growth to the market Of course, with the improvement of the overall valuation of the industry, the bubble may also be inevitable The equity investment industry said frankly However, according to the statistical analysis report on China's venture capital market in the first quarter of 2011 released recently by ChinaVenture, in the first quarter of this year, the number of PE investment cases and investment amount in the field of health care accounted for 5% and 1% respectively, ranking lower The amount and amount of VC investment accounted for 4% and 2% respectively It can be said that the biomedical industry, which was very active in the investment field last year, entered the market of "small rest" in the first quarter of this year Judging from the number and amount of investment cases, biomedical industry has quietly withdrawn from the top three positions But that doesn't mean the pharmaceutical industry lacks capital "It has always been capital chasing projects, not projects chasing capital Capital is not the first What our pharmaceutical industry lacks is good products and technology At present, there are not many good products and projects in China " Xu Ming pointed out "Last year, capital actively flowed into the biomedical industry After a round of competition, it is normal that there is a temporary correction Once a good project appears, capital will still follow in, and the pharmaceutical sector is still the hot spot of capital pursuit in the future In addition, the liquidity continued to tighten in the first quarter, and the capital was tighter than last year, which may also lead to a decline in investment " The above equity investment insiders also told reporters In recent years, pharmaceutical companies have been chasing the general drug market, but new drugs with high technology, high investment and long cycle have not been "out of favor", and technological innovation has never been abandoned On the contrary, technological innovation and new drug projects, such as biomedical research and development, are powerful magnets to attract capital "In China, new molecular entities are growing faster and faster In 2009, the number of new molecular entities increased by 20 times compared with that in 2000, with a compound annual growth rate of 45% In 2008 alone, it increased by 58% compared with that in 2007 " Gao Ruige said at the meeting According to statistics disclosed by chinabio, 3199 new molecular entities (NME) have been approved in China In terms of geographical distribution, the largest number of new molecular entities is in Shanghai, with 719 species in total, accounting for 22% of the national total The number of new molecular entities in Beijing is 615, accounting for 20% of the national total, ranking second in the country Among them, Beijing has the largest number of biological products in the country The number of new molecular entities in Shanghai and Beijing is nearly half of that in China According to statistics, among the new molecular entities, anti-tumor drugs are the most, accounting for 44%; infectious disease drugs are the second, accounting for 17%; endocrine and metabolic drugs are the third, accounting for 8%; cardiovascular drugs, immune and anti allergic drugs are 7%, and nerve center drugs are 6% According to the statistical data disclosed by chinabio, from 2004 to 2010, 181 new drugs in China were approved by SFDA; 28 new drugs were listed, including 11 new molecular entities (NME); 131 new drugs entered clinical circulation; in addition, more than 200 new drugs are in pre clinical development In clinical trials, there are 56 anti-tumor drugs, accounting for 31%; 38 infectious drugs, accounting for 21%; 23 cardiovascular drugs, accounting for 13%; 16 endocrine and metabolic drugs, accounting for 9%; 15 immune and anti allergic drugs, accounting for 8%; and other kinds of new drugs, accounting for 18% Among the approved new drugs, protein and peptide are the most "New drugs are the core driving force to promote the rapid development of the whole industry China's new drugs are still in its infancy, but in the next 5-10 years, it is likely to usher in a small peak of new drugs, which will also bring the overall high-speed development of the industry." Chen Yangui, vice president of dongyangguang Pharmaceutical Research Institute, who attended the meeting, told reporters.